Two biologics equally effective for extraintestinal manifestations of IBDOctober 27, 2022Psoriatic ArthritisPsoriasis
FDA approves upadacitinib (Rinvoq) for sixth indicationOctober 24, 2022Psoriatic ArthritisAtopic Dermatitis
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohortOctober 20, 2022Psoriatic ArthritisPsoriasisHair & NailsAtopic DermatitisPigmentation DisordersPediatrics
Climate change: Commentary in four dermatology journals calls for emergency actionOctober 17, 2022Business of MedicineAtopic DermatitisPsoriasisPsoriatic ArthritisInfectious Diseases
A White female presented with pustules and erythematous macules on the left palmOctober 14, 2022PsoriasisPsoriatic Arthritis
Previous endemic coronavirus encounters linked with long COVIDOctober 11, 2022Long COVIDPsoriatic Arthritis
Analysis of PsA guidelines reveals much room for improvement on conflicts of interestOctober 6, 2022Psoriatic Arthritis
Apremilast may have some cardiometabolic benefits in patients with psoriasisSeptember 27, 2022PsoriasisPsoriatic ArthritisMixed Topics
Psoriasis, psoriatic arthritis insurance coverage remains restrictiveSeptember 26, 2022Psoriatic ArthritisPsoriasis
Apremilast alleviates severe psoriasis in some children, data showSeptember 20, 2022PsoriasisPsoriatic ArthritisPediatrics
Brodalumab suicide risk similar to other biologics, postmarket study findsSeptember 19, 2022PsoriasisPsoriatic ArthritisMixed Topics
Sustained response at 2 years reported for newly approved oral psoriasis agentSeptember 15, 2022PsoriasisPsoriatic Arthritis
FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasisSeptember 12, 2022PsoriasisPsoriatic Arthritis
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?September 8, 2022Psoriatic ArthritisPsoriasis
